Curist

For adults, the standard dosage of terbinafine depends heavily on the location and severity of the fungal infection. According to standard clinical protocols (2024):

• Onychomycosis (Fingernail): The typical dose is 250 mg once daily for 6 weeks.
• Onychomycosis (Toenail): Because toenails grow slower and are often more severely affected, the standard dose is 250 mg once daily for 12 weeks.
• Tinea Corporis or Tinea Cruris: If oral therapy is deemed necessary, 250 mg once daily for 2 to 4 weeks is common.
• Tinea Pedis: For resistant athlete's foot, 250 mg once daily for 2 to 6 weeks may be prescribed.

Terbinafine oral granules are FDA-approved for children 4 years of age and older for the treatment of tinea capitis. The dosage is typically based on the child's weight:

• Less than 25 kg: 125 mg once daily for 6 weeks.
• 25 kg to 35 kg: 187.5 mg once daily for 6 weeks.
• Greater than 35 kg: 250 mg once daily for 6 weeks.

Healthcare providers generally do not recommend oral terbinafine for children under 4 years of age or for the treatment of onychomycosis in pediatric patients unless the benefits clearly outweigh the risks.

Renal Impairment

For patients with significant kidney dysfunction (creatinine clearance less than or equal to 50 mL/min), the use of oral terbinafine is generally not recommended. If it must be used, the dose may need to be reduced, and the patient must be monitored very closely for toxicity.

Hepatic Impairment

Terbinafine is strictly contraindicated (should not be used) in patients with chronic or active hepatic (liver) disease. Because the drug is extensively metabolized by the liver, impaired function can lead to dangerously high levels of the drug and further liver damage.

Elderly Patients

In geriatric populations, healthcare providers typically assess renal and hepatic function before prescribing. While age itself does not require a dose adjustment, the higher prevalence of decreased organ function in the elderly necessitates caution.

To ensure the best results and minimize side effects, follow these guidelines:

• Consistency: Take the medication at the same time every day to maintain steady levels in your bloodstream.
• With or Without Food: Terbinafine tablets can be taken with or without food. However, taking it with a meal may help if you experience stomach upset.
• Swallow Whole: Tablets should be swallowed whole with a glass of water. Do not crush or chew them unless specifically instructed by your pharmacist.
• Oral Granules: For the granule formulation, sprinkle the contents of the packet onto a spoonful of non-acidic food (like pudding or mashed potatoes). Do not use applesauce or fruit juice, as the acidity can affect the drug. Swallow the mixture immediately without chewing the granules.
• Storage: Store at room temperature (68°F to 77°F), away from moisture, heat, and direct light.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose (within 4 hours), skip the missed dose and resume your regular schedule. Never 'double up' on doses to make up for a missed one, as this increases the risk of side effects.

Symptoms of a terbinafine overdose may include severe nausea, vomiting, stomach pain, dizziness, or frequent urination. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. There is no specific antidote for terbinafine; treatment is generally supportive and focused on managing symptoms.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not stop taking the medication early, even if the infection appears to be gone, as the fungus may still be present and could return if the full course is not completed.

Most patients tolerate terbinafine well, but some may experience mild to moderate side effects. These often resolve as the body adjusts to the medication:

• Gastrointestinal Issues: Diarrhea, indigestion (dyspepsia), and abdominal pain are the most frequently reported. These usually occur shortly after taking the dose.
• Headache: A common complaint that can often be managed with over-the-counter pain relievers (after consulting your doctor).
• Skin Reactions: Mild rashes or itching (urticaria) may occur.
• Taste Disturbances: Some patients report a metallic or bitter taste in the mouth (dysgeusia). In rare cases, this can lead to a complete loss of taste (ageusia), which may persist for several weeks after stopping the drug.

• Nausea and Flatulence: General stomach discomfort and gas.
• Visual Disturbances: Blurred vision or decreased visual acuity have been reported in a small percentage of patients.
• Fatigue: A general feeling of tiredness or lethargy.
• Muscle and Joint Pain: Arthralgia (joint pain) and myalgia (muscle pain) may occur during treatment.

• Hepatotoxicity: Serious liver injury, though rare, is a significant concern. This can manifest as jaundice (yellowing of the skin/eyes), dark urine, or pale stools.
• Hematologic Changes: Rare cases of low white blood cell counts (neutropenia) or low platelet counts (thrombocytopenia) have been documented.
• Psoriasiform Eruptions: Terbinafine may trigger or exacerbate psoriasis in susceptible individuals.

> Warning: Stop taking Terbinafine and call your doctor immediately if you experience any of the following:

1. 1Signs of Liver Failure: Persistent nausea, loss of appetite, upper stomach pain, extreme tiredness, or yellowing of the skin or eyes.
2. 2Severe Skin Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). These are medical emergencies characterized by flu-like symptoms followed by a painful rash that spreads and blisters.
3. 3Anaphylaxis: Signs of a severe allergic reaction, including swelling of the face, tongue, or throat, difficulty breathing, or hives.
4. 4Depressive Symptoms: Some patients have reported mood changes, feelings of worthlessness, or suicidal thoughts while taking terbinafine.
5. 5Lupus-like Syndrome: New or worsening symptoms of systemic lupus erythematosus, such as a 'butterfly' rash on the cheeks or joint pain.

While terbinafine is typically taken for 6 to 12 weeks, its long-term presence in the body's tissues means side effects can occasionally emerge late in treatment or shortly after completion. The most notable long-term concern is the persistence of taste or smell disturbances, which in very rare instances can take months to fully resolve. There is no evidence that terbinafine causes permanent organ damage if used correctly and monitored by a physician, but the potential for delayed liver issues necessitates vigilance even after the final dose.

As of 2026, the FDA has not issued a formal 'Black Box Warning' for terbinafine tablets. However, the labeling contains prominent 'Warnings and Precautions' regarding hepatotoxicity. The FDA mandates that healthcare providers perform liver function tests (LFTs) before starting oral terbinafine and monitor patients for any clinical signs of liver injury throughout the treatment course. This warning is considered as serious as a black box warning by most clinical pharmacologists.

Report any unusual symptoms to your healthcare provider immediately. Early detection of side effects is key to preventing serious complications.

Terbinafine is a potent systemic medication that requires careful medical supervision. It is not suitable for everyone, particularly those with pre-existing liver conditions. Patients must be transparent with their healthcare providers regarding their full medical history, including any history of autoimmune diseases or kidney problems.

No FDA black box warnings for Terbinafine. However, the FDA-approved labeling includes significant warnings regarding the risk of liver failure, some cases of which have resulted in liver transplant or death. These events have occurred in patients both with and without pre-existing liver disease.

• Hepatotoxicity: This is the most critical precaution. Terbinafine is not recommended for patients with chronic or active liver disease. Healthcare providers must obtain baseline liver function tests (ALT and AST) before starting treatment. If liver enzyme levels become elevated, the drug must be discontinued immediately.
• Allergic Reactions / Anaphylaxis: While rare, severe allergic reactions can occur. Patients with a known hypersensitivity to terbinafine or any of its inactive ingredients must avoid the drug.
• Severe Neutropenia: There have been isolated reports of severe decreases in white blood cell counts. If a patient develops a fever or sore throat, they should be evaluated for potential infection and have their blood counts checked.
• Dermatologic Reactions: Serious skin conditions like Stevens-Johnson Syndrome have been reported. Any new, unexplained rash should be reported to a doctor immediately.
• Lupus Erythematosus: Terbinafine has been known to precipitate or exacerbate both cutaneous and systemic lupus erythematosus. Patients with a history of lupus should use this medication with extreme caution.

To ensure patient safety, the following monitoring is typically recommended:

1. 1Liver Function Tests (LFTs): Mandatory baseline testing of serum transaminases (ALT and AST). Some clinicians may repeat these tests midway through a 12-week course.
2. 2Complete Blood Count (CBC): May be performed if the patient shows signs of infection or unusual bruising, to check for neutropenia or thrombocytopenia.
3. 3Clinical Monitoring: Patients should be advised to self-monitor for signs of liver dysfunction (jaundice, dark urine) or skin changes.

Terbinafine generally does not affect the ability to drive or operate machinery. However, if you experience dizziness or visual disturbances as a side effect, you should avoid these activities until the symptoms resolve.

While there is no direct chemical interaction between alcohol and terbinafine, alcohol consumption can put additional stress on the liver. Since terbinafine carries a risk of hepatotoxicity, healthcare providers strongly advise limiting or avoiding alcohol during the course of treatment to minimize the risk of liver injury.

Terbinafine does not require a tapering period and does not carry a risk of withdrawal syndrome. However, it is vital to complete the full prescribed course. Stopping the medication early because the nail 'looks better' is a common mistake; the nail must grow out completely to ensure the fungus is eradicated, which can take several months after the drug is finished.

> Important: Discuss all your medical conditions with your healthcare provider before starting Terbinafine, especially if you have a history of liver disease, kidney disease, or a weakened immune system.

While few drugs are strictly contraindicated, the following should be avoided or managed with extreme caution due to the risk of severe adverse effects:

• Thioridazine: Terbinafine significantly increases the levels of thioridazine (an antipsychotic) by inhibiting its metabolism via CYP2D6. High levels of thioridazine can cause dangerous heart rhythm problems (QT prolongation). This combination is generally contraindicated.

Because terbinafine is a potent inhibitor of the enzyme CYP2D6, it can increase the blood levels of many drugs metabolized by this pathway:

• Tricyclic Antidepressants (TCAs): Drugs like amitriptyline and nortriptyline may reach toxic levels, leading to sedation and cardiac issues.
• Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine and paroxetine levels may increase, raising the risk of serotonin syndrome.
• Beta-Blockers: Medications like metoprolol and carvedilol may have enhanced effects, potentially leading to an abnormally slow heart rate (bradycardia) or low blood pressure.
• Antiarrhythmics: Drugs such as flecainide and propafenone require careful monitoring as their therapeutic index is narrow.

• Rifampin: This antibiotic is a potent inducer of liver enzymes. It can speed up the metabolism of terbinafine, reducing its concentration in the blood by up to 100% and making the antifungal treatment ineffective.
• Cimetidine: This H2 blocker (used for heartburn) can inhibit the metabolism of terbinafine, increasing its blood levels and the risk of side effects.
• Cyclosporine: Terbinafine may decrease the plasma concentration of cyclosporine, potentially leading to organ transplant rejection if levels are not monitored and adjusted.

• Caffeine: Terbinafine may decrease the clearance of caffeine by about 19%, potentially leading to increased heart rate, jitteriness, or insomnia in sensitive individuals.
• High-Fat Meals: While food does not prevent absorption, a very high-fat meal may slightly increase the peak concentration of terbinafine, though this is rarely clinically significant.
• Dairy: Unlike some other medications, dairy does not interfere with terbinafine absorption.

• St. John's Wort: This supplement induces CYP3A4 and may potentially reduce the efficacy of terbinafine, similar to rifampin.
• Milk Thistle: While often taken for 'liver support,' there is no clinical evidence that it prevents terbinafine-induced hepatotoxicity, and it should not be used as a substitute for medical monitoring.

Terbinafine does not typically interfere with standard laboratory tests, but as mentioned, it will cause elevations in ALT and AST if liver injury occurs. It does not generally cause false positives on urine drug screens.

For each major interaction, the management strategy usually involves either selecting an alternative medication, adjusting the dose of the interacting drug, or increasing the frequency of clinical monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

There are specific scenarios where terbinafine must NEVER be used because the risks far outweigh any potential benefit:

1. 1Chronic or Active Hepatic Disease: Because terbinafine is metabolized by the liver and has a known risk of hepatotoxicity, using it in a patient with an already compromised liver can lead to acute liver failure. This is the most significant absolute contraindication.
2. 2Hypersensitivity: Any patient who has had a previous severe allergic reaction (anaphylaxis, angioedema, or severe rash) to terbinafine or any allylamine antifungal must not take this medication.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Renal Impairment: Patients with a creatinine clearance of 50 mL/min or less should generally avoid terbinafine, as the metabolites can accumulate to toxic levels.
• Immunocompromised States: Patients with HIV/AIDS or those undergoing chemotherapy may be at a higher risk for rare blood disorders (like neutropenia) while taking terbinafine.
• Autoimmune Disorders: Specifically Systemic Lupus Erythematosus (SLE) or Psoriasis, as terbinafine can cause flares of these conditions.
• Pregnancy: While not strictly contraindicated in all regions, the treatment of onychomycosis is considered a 'cosmetic' issue that can almost always be delayed until after pregnancy to avoid any fetal risk.

There is a potential for cross-sensitivity between terbinafine and other allylamine antifungals, such as naftifine. If a patient has reacted poorly to topical naftifine, they should be monitored closely if oral terbinafine is initiated, although the risk is considered low.

> Important: Your healthcare provider will evaluate your complete medical history, including baseline blood work, before prescribing Terbinafine to ensure it is safe for you.

Terbinafine was previously classified as FDA Pregnancy Category B. Animal studies have not shown evidence of fetal harm or impaired fertility. However, there are no adequate and well-controlled studies in pregnant women. Because the treatment of fungal nail infections is elective and not life-threatening, clinical guidelines generally recommend delaying oral terbinafine therapy until after pregnancy is complete. If a patient becomes pregnant while taking terbinafine, they should stop the medication and contact their obstetrician.

Terbinafine is excreted in human breast milk. Following oral administration, the ratio of terbinafine in milk to plasma is approximately 7:1. Because of the potential for adverse reactions in nursing infants, the use of oral terbinafine is generally not recommended for women who are breastfeeding. If treatment is essential, an alternative feeding method should be considered.

Terbinafine is approved for the treatment of tinea capitis in children aged 4 years and older. The safety and efficacy for onychomycosis in children have not been established in large-scale clinical trials. Pediatric patients require weight-based dosing and should be monitored for the same side effects as adults, particularly taste disturbances and skin rashes.

Clinical studies have not identified significant differences in responses between the elderly and younger patients. However, older adults are more likely to have decreased renal or hepatic function. A thorough review of the patient's medication list is essential for the elderly, as they are more likely to be taking drugs metabolized by CYP2D6 (such as certain heart medications or antidepressants).

In patients with moderate to severe renal impairment (CrCl ≤ 50 mL/min), the clearance of terbinafine is reduced by approximately 50%. There are no specific guidelines for dose reduction; instead, the current recommendation is to avoid use in this population entirely. Terbinafine is not significantly cleared by hemodialysis.

Terbinafine is contraindicated in patients with active or chronic liver disease. In patients with pre-existing stable hepatic impairment, the clearance of terbinafine can be reduced by 50%, leading to doubled blood concentrations. Due to the inherent risk of drug-induced liver injury, terbinafine should not be initiated in these patients.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are planning a pregnancy or have underlying organ dysfunction.

Terbinafine is an allylamine that inhibits the enzyme squalene epoxidase in the fungal sterol biosynthesis pathway. By blocking this enzyme, terbinafine prevents the conversion of squalene to lanosterol. This leads to a deficiency in ergosterol, which is essential for fungal cell membrane integrity. Simultaneously, the accumulation of intracellular squalene exerts a toxic effect, leading to rapid fungal cell death. This dual action makes terbinafine fungicidal against dermatophytes.

Terbinafine shows high specificity for fungal squalene epoxidase compared to the human version of the enzyme, which explains its relatively low toxicity in humans. The drug's effect is concentration-dependent. It is highly effective against Trichophyton species, Microsporum canis, and Epidermophyton floccosum. Its activity against yeasts (like Candida) varies and is often fungistatic rather than fungicidal.

| Parameter | Value |

|---|---|

| Bioavailability | ~40% (due to first-pass metabolism) |

| Protein Binding | >99% |

| Half-life | ~36 hours (steady state); ~200-400 hours (terminal) |

| Tmax | 2 hours |

| Metabolism | Hepatic (CYP2C9, 2C19, 3A4, 1A2) |

| Excretion | Renal 70%, Fecal 20% |

• Molecular Formula: C21H25N•HCl
• Molecular Weight: 327.9 g/mol (as hydrochloride salt)
• Solubility: Slightly soluble in water; very soluble in ethanol and methanol.
• Structure: A tertiary allylamine with a naphthalene ring and an acetylene group.

Terbinafine belongs to the Allylamine class of antifungals. It is distinct from the Azole class (e.g., ketoconazole) and the Polyene class (e.g., amphotericin B). Within the allylamine class, it is the most potent and widely used systemic agent.